These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 22761338)

  • 1. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective.
    Le DT; Jaffee EM
    Cancer Res; 2012 Jul; 72(14):3439-44. PubMed ID: 22761338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer.
    Noguchi M; Moriya F; Koga N; Matsueda S; Sasada T; Yamada A; Kakuma T; Itoh K
    Cancer Immunol Immunother; 2016 Feb; 65(2):151-60. PubMed ID: 26728480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.
    Kwa M; Li X; Novik Y; Oratz R; Jhaveri K; Wu J; Gu P; Meyers M; Muggia F; Speyer J; Iwano A; Bonakdar M; Kozhaya L; Tavukcuoglu E; Budan B; Raad R; Goldberg JD; Unutmaz D; Adams S
    Breast Cancer Res Treat; 2018 Feb; 168(1):57-67. PubMed ID: 29124456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting regulatory T cells for improving cancer therapy: Challenges and prospects.
    Dwarakanath BS; Farooque A; Gupta S
    Cancer Rep (Hoboken); 2018 Jun; 1(1):e21105. PubMed ID: 32729245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma.
    Klein O; Davis ID; McArthur GA; Chen L; Haydon A; Parente P; Dimopoulos N; Jackson H; Xiao K; Maraskovsky E; Hopkins W; Stan R; Chen W; Cebon J
    Cancer Immunol Immunother; 2015 Apr; 64(4):507-18. PubMed ID: 25662405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T regulatory cells in cancer: recent advances and therapeutic potential.
    Elkord E; Alcantar-Orozco EM; Dovedi SJ; Tran DQ; Hawkins RE; Gilham DE
    Expert Opin Biol Ther; 2010 Nov; 10(11):1573-86. PubMed ID: 20955112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
    Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
    J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer.
    Chaudhary B; Abd Al Samid M; al-Ramadi BK; Elkord E
    Expert Opin Biol Ther; 2014 Jul; 14(7):931-45. PubMed ID: 24661020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metronomic cyclophosphamide induces regulatory T cells depletion and PSA-specific T cells reactivation in patients with biochemical recurrent prostate cancer.
    Laheurte C; Thiery-Vuillemin A; Calcagno F; Legros A; Simonin H; Boullerot L; Jacquin M; Nguyen T; Mouillet G; Borg C; Adotévi O
    Int J Cancer; 2020 Aug; 147(4):1199-1205. PubMed ID: 31749145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine.
    Peng S; Lyford-Pike S; Akpeng B; Wu A; Hung CF; Hannaman D; Saunders JR; Wu TC; Pai SI
    Cancer Immunol Immunother; 2013 Jan; 62(1):171-82. PubMed ID: 23011589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological and angiogenic markers during metronomic temozolomide and cyclophosphamide in canine cancer patients.
    Denies S; Cicchelero L; de Rooster H; Daminet S; Polis I; Van de Maele I; Sanders NN
    Vet Comp Oncol; 2017 Jun; 15(2):594-605. PubMed ID: 26961119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome.
    Ge Y; Domschke C; Stoiber N; Schott S; Heil J; Rom J; Blumenstein M; Thum J; Sohn C; Schneeweiss A; Beckhove P; Schuetz F
    Cancer Immunol Immunother; 2012 Mar; 61(3):353-62. PubMed ID: 21915801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I lead-in and subsequent randomized trial assessing safety and modulation of regulatory T cell numbers following a maximally tolerated dose doxorubicin and metronomic dose cyclophosphamide combination chemotherapy protocol in tumour-bearing dogs.
    Rasmussen RM; Kurzman ID; Biller BJ; Guth A; Vail DM
    Vet Comp Oncol; 2017 Jun; 15(2):421-430. PubMed ID: 26522053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoregulatory Cell Depletion Improves the Efficacy of Photodynamic Therapy-Generated Cancer Vaccines.
    Korbelik M; Banáth J; Saw KM
    Int J Mol Sci; 2015 Nov; 16(11):27005-14. PubMed ID: 26569233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo.
    Tongu M; Harashima N; Monma H; Inao T; Yamada T; Kawauchi H; Harada M
    Cancer Immunol Immunother; 2013 Feb; 62(2):383-91. PubMed ID: 22926062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication.
    Denies S; Cicchelero L; Van Audenhove I; Sanders NN
    J Control Release; 2014 Aug; 187():175-82. PubMed ID: 24887014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.
    Walter S; Weinschenk T; Stenzl A; Zdrojowy R; Pluzanska A; Szczylik C; Staehler M; Brugger W; Dietrich PY; Mendrzyk R; Hilf N; Schoor O; Fritsche J; Mahr A; Maurer D; Vass V; Trautwein C; Lewandrowski P; Flohr C; Pohla H; Stanczak JJ; Bronte V; Mandruzzato S; Biedermann T; Pawelec G; Derhovanessian E; Yamagishi H; Miki T; Hongo F; Takaha N; Hirakawa K; Tanaka H; Stevanovic S; Frisch J; Mayer-Mokler A; Kirner A; Rammensee HG; Reinhardt C; Singh-Jasuja H
    Nat Med; 2012 Aug; 18(8):1254-61. PubMed ID: 22842478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy using regulatory T cells in cancer suggests more flavors of hypersensitivity type IV.
    Pakravan N; Hassan ZM
    Immunotherapy; 2018 Mar; 10(3):213-219. PubMed ID: 29370722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.
    Huijts CM; Santegoets SJ; van den Eertwegh AJ; Pijpers LS; Haanen JB; de Gruijl TD; Verheul HM; van der Vliet HJ
    BMC Cancer; 2011 Nov; 11():505. PubMed ID: 22129044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial.
    Ellebaek E; Engell-Noerregaard L; Iversen TZ; Froesig TM; Munir S; Hadrup SR; Andersen MH; Svane IM
    Cancer Immunol Immunother; 2012 Oct; 61(10):1791-804. PubMed ID: 22426890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.